Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers

ABSTRACT: Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers

PROVIDER: PRJNA506989 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR8244640.fastq.gz	Fastqsanger.gz
	SRR8244641.fastq.gz	Fastqsanger.gz
	SRR8244642.fastq.gz	Fastqsanger.gz
	SRR8244643.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers

Project description:Cancer cells frequently boost nucleotide metabolism (NM) to support their increased proliferation, but the consequences of elevated NM on tumor de-differentiation are mostly unexplored. Here, we identified a role for thymidylate synthase (TS), a NM enzyme and established drug target, in cancer cell de-differentiation and investigated its clinical significance in breast cancer (BC). In vitro, TS knockdown increased the population of CD24+ differentiated cells, and attenuated migration and sphere-formation. RNA-seq profiling indicated a repression of epithelial-to-mesenchymal transition (EMT) signature genes upon TS knockdown, and TS-deficient cells showed an increased ability to invade and metastasize in vivo, consistent with the occurrence of a partial EMT phenotype. Mechanistically, TS enzymatic activity was found essential for the maintenance of the EMT/stem-like state by fueling a dihydropyrimidine dehydrogenase – dependent pyrimidine catabolism. In patient tissues, TS levels were found significantly higher in poorly differentiated and in triple negative BC, and strongly correlated with worse prognosis. The present study provides the rationale to study in-depth the role of NM at the crossroads of proliferation and differentiation, and depicts new avenues for the design of novel drug combinations for the treatment of BC

2019-02-01 | GSE122953 | GEO

Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers.

Project description:Cancer cells frequently boost nucleotide metabolism (NM) to support their increased proliferation, but the consequences of elevated NM on tumor de-differentiation are mostly unexplored. Here, we identified a role for thymidylate synthase (TS), a NM enzyme and established drug target, in cancer cell de-differentiation and investigated its clinical significance in breast cancer (BC). In vitro, TS knockdown increased the population of CD24+ differentiated cells, and attenuated migration and sphere-formation. RNA-seq profiling indicated repression of epithelial-to-mesenchymal transition (EMT) signature genes upon TS knockdown, and TS-deficient cells showed an increased ability to invade and metastasize in vivo, consistent with the occurrence of a partial EMT phenotype. Mechanistically, TS enzymatic activity was found essential for maintenance of the EMT/stem-like state by fueling a dihydropyrimidine dehydrogenase-dependent pyrimidine catabolism. In patient tissues, TS levels were found significantly higher in poorly differentiated and in triple negative BC, and strongly correlated with worse prognosis. The present study provides the rationale to study in-depth the role of NM at the crossroads of proliferation and differentiation, and depicts new avenues for the design of novel drug combinations for the treatment of BC.

| S-EPMC6888897 | biostudies-literature

Transcriptional regulation by Fra-1 in triple negative breast cancers

Project description:This SuperSeries is composed of the SubSeries listed below. All the data are described in the article "Fra-1 regulates its target genes via binding to remote enhancers without exerting major control on chromatin architecture in triple negative breast cancers" by Bejjani et al.

2021-02-23 | GSE146825 | GEO

BRCAness, SLFN11 and RB1 loss predict response to topoisomerase I inhibitors in triple negative breast cancers

Project description:Expression data from patient-derived xenografts of human triple-negative breast cancers

2019-12-28 | GSE142639 | GEO

Transcriptional regulation by Fra-1 in triple negative breast cancers

Project description:Transcriptional regulation by Fra-1 in triple negative breast cancers

| PRJNA612051 | ENA

Comparative Characterization of 3D Chromatin Organization in Triple-Negative Breast Cancers

Project description:Comparative Characterization of 3D Chromatin Organization in Triple-Negative Breast Cancers

| PRJNA703390 | ENA

Single cell RNA-seq of 25 thousand epithelial cells from xenografts of triple-negative breast cancers

Project description:Patient derived xenografts (PDX) were created from two triple-negative breast cancers (PDX-110 and PDX-332) taken at the time of surgery from drug-naive patients. Freshly sorted epithelial cells were profiled by single-cell RNA-seq (scRNA-seq) using a 10X Genomics Chromium System.

2019-02-26 | GSE123926 | GEO

Co-dependency for MET and FGFR1 in basal triple negative breast cancers

Project description:Co-dependency for MET and FGFR1 in basal triple negative breast cancers

| PRJNA681227 | ENA

Comparative Characterization of 3D Chromatin Organization in Triple-Negative Breast Cancers [Hi-C]

Project description:Comparative Characterization of 3D Chromatin Organization in Triple-Negative Breast Cancers [Hi-C]

| PRJNA703392 | ENA

Comparative Characterization of 3D Chromatin Organization in Triple-Negative Breast Cancers [ChIP-seq]

Project description:Comparative Characterization of 3D Chromatin Organization in Triple-Negative Breast Cancers [ChIP-seq]

| PRJNA703393 | ENA